RBC's Bullish Neurologist Survey Leads To A $108 Price Target On Sarepta Therapeutics

By: via Benzinga
A recent neurologist survey and the latest call with DMD KOLs support a bullish stance on the commercial prospects of Sarepta ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.